Double-blind, placebo-controlled, randomized phase III trial of oral thalidomide in advanced hepatocellular carcinoma [liver cancer] with poor liver reserve
Phase of Trial: Phase III
Latest Information Update: 07 Oct 2011
At a glance
- Drugs Thalidomide (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors TTY Biopharm
- 07 Oct 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 02 Jan 2006 New trial record.